{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:30:32Z","timestamp":1791509432492,"version":"4.3.4"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>A prospective study was carried out to examine the efficacy of cyclophosphamide and azathioprine in pemphigus vulgaris.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To compare the clinical and serological effect of azathioprine and cyclophosphamide in pemphigus patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Prospective, institutional based study was conducted twenty-one patients of pemphigus vulgaris were initiated on either azathioprine (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 9) or cyclophosphamide (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 7) in addition to prednisolone and were evaluated clinically (mucosal and cutaneous severity) and serologically enzyme-linked immunosorbent assay (ELISA) at 0, 3 and 6 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Azathioprine had a slower onset of action with a statistically significant improvement seen by 6 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.016). Cyclophosphamide had a faster onset of action (3 months) though there was no statistical difference in the efficacy between the two at the end of 6 months. The (RonT) was 33.3\u201344.4% for azathioprine and 28.8\u201342.9% for cyclophosphamide at 6 months. Though ELISA had a high sensitivity and specificity for diagnosis, as a tool for assessing therapeutic response a significant decrease was seen only till 3 months. This was restricted to Dsg1 for the azathioprine group and both Dsg3 and Dsg1 levels for the cyclophosphamide group. There were two deaths, both in the cyclophosphamide group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Azathiorpine and cyclophosphamide are equally effective for mucosal and cutaneous disease in pemphigus after 6 months of therapy. Dsg ELISA is useful for diagnosis of pemphigus but is not a useful tool for monitoring response to therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0019-5154.185710","type":"journal-article","created":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T00:18:48Z","timestamp":1468282728000},"page":"418-426","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["A Comparative Effectiveness Research of Azathioprine and Cyclophosphamide on the Clinical and Serological Response in Pemphigus Vulgaris"],"prefix":"10.4103","volume":"61","author":[{"given":"Kabir","family":"Sardana","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Maulana Azad Medical College, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Agarwal","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Maulana Azad Medical College, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Bansal","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Maulana Azad Medical College, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beena","family":"Uppal","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Maulana Azad Medical College, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K","family":"Garg","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Maulana Azad Medical College, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clindermatol.2011.03.014","article-title":"Current therapy of the pemphigus group","volume":"30","author":"Kasperkiewicz","year":"2012","journal-title":"Clin Dermatol"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clindermatol.2009.06.018","article-title":"Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: Facts and controversies","volume":"28","author":"Schiavo","year":"2010","journal-title":"Clin Dermatol"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.det.2011.07.001","article-title":"Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus","volume":"29","author":"Frew","year":"2011","journal-title":"Dermatol Clin"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/11530050-000000000-00000","article-title":"Oropharyngeal pemphigus vulgaris and clinical remission: A long-term, longitudinal study","volume":"11","author":"Mignogna","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","article-title":"Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris","volume":"57","author":"Chams-Davatchi","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R6-20250605","first-page":"300","article-title":"Treatment of pemphigus: A local experience","volume":"48","author":"Akhtar","year":"1998","journal-title":"J Pak Med Assoc"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00128071-200708020-00004","article-title":"Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris","volume":"8","author":"Olszewska","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1610-0378.2005.04747.x","article-title":"Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: Results of a multicenter prospectively randomized study","volume":"3","author":"Rose","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1001\/archderm.142.11.1447","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus","volume":"142","author":"Beissert","year":"2006","journal-title":"Arch Dermatol"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/11311150-000000000-00000","article-title":"Dexamethasone-cyclophosphamide pulse therapy in pemphigus: A review of 72 cases","volume":"11","author":"Zivanovic","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1067\/S0190-9622(03)00859-4","article-title":"Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus","volume":"49","author":"Cummins","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-4362.1994.tb01003.x","article-title":"Treatment of oral pemphigus vulgaris","volume":"33","author":"Chrysomallis","year":"1994","journal-title":"Int J Dermatol"},{"key":"R13-20250605","first-page":"187864","article-title":"Detection of autoantibodies against recombinant desmoglein 1 and 3 molecules in patients with pemphigus vulgaris: Correlation with disease extent at the time of diagnosis and during follow-up","author":"Belloni-Fortina","year":"2009","journal-title":"Clin Dev Immunol 2009"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1600-0625.2006.00499_1.x","article-title":"Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just witnesses of disease?","volume":"15","author":"Amagai","year":"2006","journal-title":"Exp Dermatol"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/08916934.2011.606444","article-title":"Pemphigus autoimmunity: Hypotheses and realities","volume":"45","author":"Grando","year":"2012","journal-title":"Autoimmunity"},{"key":"R17-20250605","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjd.12012","article-title":"Is there an emergent need to modify the desmoglein compensation theory in pemphigus on the basis of Dsg ELISA data and alternative pathogenic mechanisms?","volume":"168","author":"Sardana","year":"2013","journal-title":"Br J Dermatol"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0733-8635(05)70006-1","article-title":"Immunosuppressive agents in dermatology. An update","volume":"16","author":"Dutz","year":"1998","journal-title":"Dermatol Clin"},{"key":"R21-20250605","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/j.1468-3083.2011.04294.x","article-title":"Utility of desmoglein ELISA in the clinical correlation and disease monitoring of pemphigus vulgaris","volume":"26","author":"Anand","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R22-20250605","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archdermatol.2009.9","article-title":"ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus","volume":"145","author":"Abasq","year":"2009","journal-title":"Arch Dermatol"},{"key":"R23-20250605","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2133.2001.04132.x","article-title":"The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels","volume":"144","author":"Harman","year":"2001","journal-title":"Br J Dermatol"},{"key":"R24-20250605","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2133.2000.03660.x","article-title":"A study of desmoglein 1 autoantibodies in pemphigus vulgaris: Racial differences in frequency and the association with a more severe phenotype","volume":"143","author":"Harman","year":"2000","journal-title":"Br J Dermatol"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1046\/j.1365-2133.2002.04838.x","article-title":"Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3","volume":"147","author":"Cheng","year":"2002","journal-title":"Br J Dermatol"},{"key":"R27-20250605","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jama.298.10.1209","article-title":"Limitations of applying summary results of clinical trials to individual patients: The need for risk stratification","volume":"298","author":"Kent","year":"2007","journal-title":"JAMA"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00076423-201661040-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:20:56Z","timestamp":1787836856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00076423-201661040-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/0019-5154.185710","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"2015-04-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-06-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}